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Background: The relationship between substance use disorders and psychiatric pathology is still an open question.
The main aim of the present study was to verify whether the five psychopathological dimensions identified through
the SCL-90 tool in a previous study carried out on patients with heroin addiction entering an outpatient opioid agonist
treatment (OAT) were also observable in those entering a residential treatment community (TC). Further aims were to
look at differences in the psychopathological profiles of patients entering a TC versus an OAT treatment and at the
correlation between gender and the observed psychopathology.
Methods: A confirmatory factor analysis was performed on the results of SCL-90 filled by 1,195 patients with heroin
dependence entering TC treatment. It replicates the extraction method previously used on 1,055 OAT patients with
heroin addiction by using a principal component factor analysis (PCA). The association between the kind of treatment
received (TC or OAT), gender, and the psychopathological dimensions was assessed through logistic regression and
general linear model (GLM) analysis.
Results: The PCA carried out on the SCL-90 results of patients entering a TC yielded a five-factor solution, confirming
the same dimensions observed in patients entering an OAT: ‘worthlessness and being trapped’, ‘somatization’,
‘sensitivity-psychoticism’, ‘panic anxiety’, and ‘violence-suicide’. The logistic regression analysis showed a statistically
significant association between ‘somatization’ and ‘violence-suicide’ severity score and OAT. GLM analysis showed
that psychopathological factorial scores for ‘worthlessness-being trapped’, ‘somatic symptoms’, and ‘panic anxiety’
dimensions were more severe in OAT vs TC male patients and in TC vs OAT female ones. ‘Violence suicide’ followed
the same severity pattern for males, but did not differ in TC vs OAT females, while ‘sensitivity-psychoticism’ did not
differ in OAT vs TC patients. The five dimensions did not differ in OAT males vs females.
Conclusions: Our research appears to confirm the existence of a specific aggregation of psychological/psychiatric
features within the category of individuals with heroin addiction. It also shows a correlation between the dominant
psychopathological subgroup and the assignment to TC versus OAT. Further research is needed to clarify the
differences between the five psychopathological subgroups and their determinants.
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The relationship between substance use and other psy-
chiatric disorders is still an open question. According
to current nosographic approaches—especially the one
followed by the Diagnostic and Statistical Manual of
Mental Disorders (DSM) system, even in its recent fifth
version [1]—substance use disorders are defined by the
core symptoms of addiction, such as continuation of
use despite consequences, reduction of other interests and
activities, and craving. Other relevant psychopathological
symptoms present in the clinical picture of persons with
addictive behaviours are included in separate disorders
pertaining to the domain of psychiatric ‘comorbidity’.
Several findings challenge this ‘dividing’ approach to
unitary clinical presentations: besides the high degree
of association between core symptoms of addiction and
other psychiatric symptoms [2-4], various neurobiological
and clinical considerations highlight the strong link
between addiction as such and other forms of psycho-
pathology [5-10]. Accordingly, a revision of the current
nosology is needed, moving to approaches based on
dimensions of observable behaviour and neurobiological
measures [11]. On these bases, an integrated, unified
approach, which aims to explain the pathophysiology
and phenomenology of addiction, including psychological/
psychiatric precursors, acute substance effects, addictive
processes, and psychiatric consequences, has been previ-
ously proposed [12,13]. Actually, a clinical diagnosis of a
psychiatric disorder in the presence of substance addiction
is a difficult task. The short- and long-term effects of
substances, their withdrawal, and the consequences of
addictive processes result in symptoms that cannot be
clearly distinguished from those produced by independent
psychiatric disorders or psychological conditions preceding
substance use. The use of structured and semi-structured
interviews has certainly improved the reliability of comor-
bid psychiatric diagnoses. However, even with the support
of these interviews, the reliability of diagnoses remains
weak [14-18].
Given this background, and the consequent uncertainty
in the correct classification of symptomatology as being
intrinsic to the addictive disorder or as due to comorbidity,
a low level of inference has been considered in approaching
the psychopathology of addiction, while focusing primarily
on the symptoms expressed by patients rather than starting
from a pre-established syndromic level such as that of the
DSM [19-22].
Following this approach, some years ago, our research
group applied an exploratory principal component factor
analysis (PCA) to symptoms shown by a sample of patients
entering an outpatient opioid agonist treatment (OAT) in
the city of Pisa [21]. The analysis yielded a three-factor
solution identifying 1) a ‘depressive-anxious’ dimension
(illness awareness, anxiety state, depressed mood, sleepand eating disturbances), 2) a ‘psychomotor excitement’
dimension (hypomanic/manic or mixed state, aggres-
siveness and violence, suicidality), 3) and a ‘psychotic
state’ dimension, including memory deficits, altered
consciousness, delusions, and hallucinations. Adopting
a similar approach, Zack et al. applied a PCA to the 90
items listed in the SCL-90 questionnaire administered to a
population of 740 outpatients with coexisting substance
use (especially alcohol) and psychiatric disorders. This
analysis yielded three inter-correlated factors that, taken
together, accounted for 38% of the variance found in
ratings from the entire sample: the first factor was charac-
terized by anxious and depressive symptoms and identified
as ‘general emotional distress’; the second factor reflected
a combination of bodily concerns and phobic avoidance
and was labelled ‘panic-related symptoms’, and the third
factor contained elements of hostile thought and behav-
iour as well as suspicious beliefs and was identified as
‘hostility and suspiciousness’. In any case, a single higher-
order factor was identified that explained 60% of the
variance in factor scores. This study also tested the factor
structure variations measured by the SCL-90 across
gender—a subject on which inconsistencies had been
reported in previous studies—so demonstrating a structural
similarity between the factors as they appear separately in
each gender [20].
In a further investigation carried out by our group, the
SCL-90 checklist was used to investigate the psycho-
pathological dimensions of 1,055 patients with heroin
addiction who had been admitted to public addiction
facilities in Italy and were beginning an OAT. By applying
an exploratory PCA to the 90 items in SCL-90, a five-factor
solution was identified: the first factor reflected a depressive
‘worthlessness and being trapped’ dimension, the second
factor picked out a ‘somatization’ dimension, the third iden-
tified a ‘sensitivity-psychoticism’ dimension, the fourth a
‘panic anxiety’ dimension, and the fifth a ‘violence-suicide’
dimension [22]. Overall, the five factors accounted for
37.8% of the variance found between the items.
The main aim of the present study was to verify
whether the five psychopathological dimensions identified
in the previous study carried out with patients entering
an OAT were also observable in subjects with heroin
addiction entering a treatment community (TC). Further
aims were to look at differences in the psychopathological
profile of patients entering a TC versus an OAT treatment
and to look at the correlation between gender and the
psychopathology expressed through the SCL-90 by the
enrolled patients.
Our expectations were that psychopathological sub-
types previously observed in opioid dependents would
be confirmed in a different sample of opioid dependents,
that the severity of patients’ psychopathology would be
associated with the treatment modality chosen, and that
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the female population.Methods
Setting
Patients included in the present study come from two
datasets: the first is the Pisa addiction dataset, a database
that includes anonymous individual information on pa-
tients with heroin addiction receiving OAT at the Italian
Addiction Services during the years 1995–2010, infor-
mation originally collected for clinical or other research
purposes. The second is the Evaluation of Therapeutic
Community Treatments and Outcomes (VOECT) dataset,
which includes individual information on patients with
heroin addiction admitted to TC treatment in eight Italian
regions in 2008–2009 [23].Sample
The OAT sample consisted of 1,055 subjects, with diagnosis
of heroin dependence according to DSM-IV criteria; they
were evaluated at the time they entered OAT at Italian
facilities. The mean age of this sample was 30.6 ± 6.6 years,
83.9% of the subjects were male, 83.1% were single, educa-
tional level was high (studies lasting over 8 years) in 10.1%
of the sample, 56.6% of subjects were unemployed, and
22.9% were at their first treatment. Heroin history length
was 7.3 ± 6.0 years on average.
Patients in the TC cohort (n = 1,195) received the
diagnosis of heroin dependence according to clinical
judgement; they were evaluated at the time they entered
the TC. The mean age of this sample was 33.8 ± 7.7 years;
81.4% of the subjects were male, 90.2% were single,
educational level was high (studies lasting more then 8
years) in 9.3% of the sample, 72.4% of the subjects were
unemployed, and 3.2% were at their first treatment.
Heroin history length was 12.2 ± 8.1 years on average.
Considered together, the two samples gave a heteroge-
neous cohort of 2,250 subjects with a diagnosis of heroin
addiction. For the full sample, the mean age was 32.3 ±
7.4 years (range: 15–62). Of the subjects, 1,857 (82.5%)
were male, 2,032 (90.3%) had a low educational level
(studies lasting 8 years or less), 1,960 (87.1%) were
single, 1,516 (67.4%) were unemployed, and 108 (4.8%)
were unable to work due to health impairment. The
mean duration of addiction was 9.4 ± 7.4 years (min 0.8,
max 34.8). A total of 774 (34.4%) had an addiction
history lasting less than 5 years, 600 (26.7%) lasting
between 5 and 10 years, 358 (15.9%) between 10 and 15
years, 292 (13.0%) between 15 and 20 years, and 225
(10.0%) over 20 years. All these patients were of Italian
nationality and were included only once in the sample.
In all, 270 (12.0%) were beginning treatment for heroin
addiction for the first time.Instruments
After its development by Derogatis and colleagues [24],
the SCL-90 now includes 90 items, each rated on a 5-point
scale of distress. These items can be clustered in nine
dimensions: somatization, obsession-compulsion, interper-
sonal sensitivity, depression, anxiety, anger-hostility, phobic
anxiety, paranoid ideation, and psychoticism.
Four global scores can be calculated: 1) Total SCL-90
score (sum of all items); 2) General Symptomatic Index
(GSI), the mean score of all recorded items; 3) Positive
Symptoms Total (PST), the number of items rated posi-
tively; and 4) Positive Symptom Distress Index (PSDI),
which is calculated by dividing the sum of all items by
the PST score.
Information on other demographic and clinical charac-
teristics of the patients included in the study was collected
from clinical records or research questionnaires for the
Pisa dataset and from a research questionnaire for the
VOECT dataset.
Data analyses
The two groups of patients (entering OAT or TC services)
were compared for socio-demographic and clinical char-
acteristics by means of the chi-square test for categorical
variables and of Student’s t test for continuous variables.
A confirmatory factor analysis was then performed on the
SCL-90 results of the 1,195 TC patients, replicating the
same extraction method previously used on the 1,055
OAT patients [22]. Put simply, the single factors were
extracted by using a PCA (type 2) and then rotating
this orthogonally to achieve a simple structure. To limit
the number of factors, the criterion used was an eigen-
value >1.5. Items loading with absolute values >0.40
were used to identify the factors. In order to make factor
scores comparable, they were standardized into z scores.
All the subjects were then assigned to a different subtype
on the basis of the highest factor score achieved (domin-
ant SCL-90 factor). This procedure gives the opportunity
to classify subjects on the basis of the highest symptomat-
ological cluster. At this point, the correlations between
the factors extracted in the two populations under study
were estimated through Pearson correlation. Lastly, we
looked at the inter-rated reliability (Cohen’s kappa) of the
factorial analyses, applying the two factor solutions to
the TC patients. We considered a Kappa value higher
than 0.60 as indicating that the two factor solutions are
very similar [25]. Given this similarity, the factor solution
identified in the OAT sample was used to compare patients
receiving OAT with those receiving therapy in a TC.
The association between dominant psychopathological
group and the kind of treatment received (OAT and TC)
was assessed through a logistic regression analysis applied
to the whole sample of 2,250 subjects resulting from
merging the two datasets. In order to take into account
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clinical variables statistically different between TC and
OAT patients in the basic analyses were included into the
regression model: age, gender, heroin history length, previ-
ous treatments, working condition, and welfare benefits.
Finally, the general linear model (GLM) was used to
compare psychopathological factorial scores, according
to the ‘Group (OAT vs TC) + Gender + Group × Gender’
design, between the two samples of patients, adjusting for
age and heroin history length. All analyses were carried
out using SPSS v. 4.0 (SPSS, Chicago, IL, USA). Statistical
significance was set at the p = 0.05 level.
Results
Comparison between OAT and TC patients
The TC patients were older (33.87 ± 7.7 years) than the
OAT ones (30.56 ± 6.6 years). This difference was statis-
tically significant (T = −10.45; p = 0.000). Of the sample,
90.2% of the TC patients and 83.1% of the OAT patients
were single (chi-square = 23.06; p = 0.000); 72.4% and
56.6% were unemployed (chi-square = 35.35; p = 0.000);
6.6% and 2.7%, respectively, received welfare benefits (chi-
square = 18.23; p = 0.000); and 3.2% and 22.9%, respect-
ively, were at their first treatment (chi-square = 196.20;
p = 0.000). Heroin history length was longer (12.22 ±
8.1 years) in the TC patients than in the OAT ones
(7.28 ± 6.0; T = −14.28; p = 0.000).
Males were 81.4% among the TC patients and 83.9%
among the OAT patients. No differences were observed
as regards to gender: the female/male ratio was 1:4.3 for
patients in the TC sample and 1:5.2 in the OAT patients
(p = 0.131). Educational level was high (studies lasting
over 8 years) in 9.3% of the TC patients and in 10.1% of
the OAT ones (p = 0.558).
Confirmatory factor analysis
The PCA applied to the TC sample confirmed a five-
factor solution. Altogether, 76 items with a loading >0.40
were retained. ‘Worthlessness’ and ‘being trapped’ were
the two leading items in the first depressive dimension;
this accounted for 33.3% of the variance. The ‘somatization’
dimension was the second factor, accounting for 3.7% of
the variance. The third factor confirmed the ‘sensitivity-
psychoticism’ dimension; this accounted for 3.3% of the
total variance. Panic symptoms loaded on the fourth
factor, the ‘panic-anxiety’ dimension, accounting for 2.3%
of the total variance. The last, fifth factor, confirmed a
‘violence suicide’ dimension, which accounted for 2.0% of
the total variance. Overall, these five factors accounted for
44.6% of the variance between the recorded items.
On the basis of the highest z scores obtained on the
five SCL-90 factors (dominant SCL-90 factor), subjects
whose dominant factor was ‘worthlessness and being
trapped’ included 199 subjects (16.7%); the group with‘somatization’ as dominant factor comprised 207 subjects
(17.3%), the group with ‘sensitivity-psychoticism’ numbered
252 subjects (21.1%), the group with ‘panic-anxiety’ had 350
subjects (29.3%), and the group whose dominant factor was
‘violence-suicide’ was made up of a cluster of 187 subjects
(15.5%).
Correlating factorial scores derived from the exploratory
and the confirmatory factor analyses, the first factors cor-
related with a Pearson’s r = 0.80, the second with r = 0.69,
the third with r = 0.79, the fourth with r = 0.72, and the
fifth with r = 0.61. All these correlations were statistically
significant (p < 0.001).
After assigning TC patients to five mutually exclusive
groups using exploratory and confirmatory analysis,
Cohen’s kappa was 0.60.
As regards the results of the logistic regression analysis
carried out on the whole sample obtained by merging
the two groups of patients admitted to TC and OAT
(Table 1), among the five extracted factors, both the
‘somatic symptoms’ and the ‘violence-suicide’ dominant
psychopathological group membership were associated
at a statistically significant level with the OAT group
membership. Among potential confounding factors, both
the female gender and the heroin history length were
significantly associated with the TC group, whereas being
at first treatment and having a job were associated with
the OAT group. Age and presence of welfare benefits did
not enter the regression equation.
Gender and psychopathology
Table 2 shows the differences of SCL-90 indexes between
males and females in OAT and TC. Multivariate analysis
showed significant differences between the two groups
(F = 8.66; df = 4; p = 0.000), the two genders (F = 7.31;
df = 4; p = 0.000), and a group by gender interaction
(F = 8.79; df = 4; p = 0.000). In particular, total SCL-90 did
not differ between the groups; group-gender interaction
was statistically significant, with male patients in the TC
group showing lower scores and TC females higher ones
than the OAT group pairs. The same pattern was observed
for GSI. PST was higher in patients in the OAT group
than in the TC patients. The same pattern was observed
with PSDI. For all indexes, the lowest scores were found
among TC males and the highest among TC females.
Significant correlations were maintained when the age
and duration of dependence were included as covariates
(F = 2.41; p = 001). As the relationship between psycho-
pathological factorial scores and marital status (F = 1.09;
p = 0.35), employment (F = 1.19; p = 0.31), welfare bene-
fits (F = 0.08; p = 0.98), and previous treatment (F = 1.27;
p = 0.27) did not reach statistical significance (data not
shown), these variables were not included in the model.
Table 3 shows differences between males and females
in OAT and TC as regards the five SCL-90 dominant
Table 1 Logistic regression carried out in 2,250 heroin-addicted patients at treatment entry
STEP B Odds ratio Min Max P
Variables in equation
Being at first treatment 1 −2.42 0.08 0.05 0.15 0.000
Heroin history length 2 0.008 1.01 1.006 1.009 0.000
Working 3 −0.55 0.57 0.44 0.74 0.000
SCL-90 dominant groups 4 0.000
SCL-90 dominant group (somatic symptom)a −7.48 0.47 0.32 0.69 0.000
SCL-90 dominant group (sensitivity-psychoticism)a −0.19 0.82 0.54 1.23 0.344
SCL-90 dominant group (panic anxiety)a 0.16 1.01 0.68 1.51 0.938
SCL-90 dominant group (violence-suicide)a −0.41 0.66 0.43 0.99 0.049
Female gender 5 0.35 1.42 1.03 1.94 0.028
Variables not in equation
Presence of welfare benefits
Age
Statistic: chi-square 321.70, df 8, p < 001
It includes SCL-90 factors and other demographic and clinical variables as determinants, and treatment group (TC versus AOT) as a dependent variable.
aConsidering dominant ‘worthlessness-being trapped’ as reference group.
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differences between the two groups (F = 16.65; df = 5;
p = 0.000), the two genders (F = 76.39; df = 5; p = 0.000)
and group-gender interaction (F = 10.09; df = 45;
p = 0.000). In particular, the ‘worthlessness-being trapped’
dimension was more severe in patients in the OAT group
than in TC group patients, and in females within the
TC group than in males. The same pattern was observed
regarding ‘somatic symptoms’, ‘panic anxiety’, and ‘vio-
lence-suicide’. ‘Sensitivity-psychoticism’ did not differ
between the two groups, and a similar pattern was found
between the genders: males of the TC group scored low-
est, and females highest. Again, significant correlations
were maintained when age and duration of dependenceTable 2 Differences between OAT and TC patients in SCL-90 i
OAT patients
Males Females
Total SCL-90 89.67 ± 54.8 89.37 ± 54.5
General Symptomatic Index 0.99 ± 0.6 0.99 ± 0.6
Positive symptoms total 48.09 ± 18.1 47.64 ± 18.3
Positive symptom distress index 1.77 ± 0.7 1.75 ± 0.5
Gr group, Ge gender.were included as covariates (F = 2.87; p = 0.000), while the
relationship between psychopathological factorial scores
and marital status (F = 1.04; p = 0.39), employment
(F = 1.41; p = 0.21), welfare benefits (F = 0.63; p = 0.67),
and previous treatment (F = 0.38; p = 0.86) was not
statistically significant; therefore, these variables were
not included in the model.
Discussion
The primary aim of the present study was to verify
whether the five psychopathological dimensions identi-
fied through the SCL-90 in a previous study carried out
on patients entering an outpatient OAT were also observ-
able in patients with heroin addiction entering a residentialndexes by gender
TC patients Statistics
Males Females
73.95 ± 55.3 107.02 ± 58.0 Gr: F = 0.09; p = 0.759
Ge: F = 26.98; p = 0.000
Gr × Ge: F = 27.96; p = 0.000
0.82 ± 0.6 1.18 ± 0.6 Gr: F = 0.06; p = 0.799
Ge: F = 26.48; p = 0.000
Gr × Ge: F = 28.35; p = 0.000
39.92 ± 19.6 50.75 ± 19.0 Gr: F = 5.52; p = 0.019
Ge: F = 23.12; p = 0.000
Gr × Ge: F = 27.36; p = 0.000
1.69 ± 0.5 1.99 ± 0.5 Gr: F = 4.68; p = 0.031
Ge: F = 15.71; p = 0.000
Gr × Ge: F = 19.32; p = 0.000
Table 3 Differences between OAT and TC patients in SCL-90 indexes by gender
OAT patients TC patients Statistics
Males Females Males Females
Worthlessness-being trapped 1.22 ± 0.7 1.20 ± 0.7 1.04 ± 0.7 1.54 ± 0.8 Gr: F = 3.76; p = 0.052
Ge: F = 28.62; p = 0.000
Gr × Ge: F = 33.83; p = 0.000
Somatic symptoms 1.28 ± 0.7 1.27 ± 0.8 0.93 ± 0.7 1.35 ± 0.7 Gr: F = 10.12; p = 0.001
Ge: F = 22.80; p = 0.000
Gr × Ge: F = 25.14; p = 0.000
Sensitivity-psychoticism 0.82 ± 0.6 0.82 ± 0.6 0.72 ± 0.6 1.01 ± 0.7 Gr: F = 1.50; p = 0.221
Ge: F = 14.79; p = 0.000
Gr × Ge: F = 15.77; p = 0.000
Panic-anxiety 0.45 ± 0.5 0.44 ± 0.5 0.37 ± 0.5 0.67 ± 0.6 Gr: F = 4.44; p = 0.035
Ge: F = 18.30; p = 0.000
Gr × Ge: F = 20.70; p = 0.000
Violence-suicide 0.94 ± 0.7 1.01 ± 0.7 0.74 ± 0.6 1.00 ± 0.7 Gr: F = 6.60; p = 0.010
Ge: F = 16.19; p = 0.000
Gr × Ge: F = 6.07; p = 0.014
Gr group, Ge gender.
Pani et al. Annals of General Psychiatry 2014, 13:35 Page 6 of 10
http://www.annals-general-psychiatry.com/content/13/1/35TC. Additional aims were to look at differences in the
psychopathological profile of subjects entering a TC
versus an OAT treatment and to look at the correlation
between gender and the observed psychopathology.
The factorial analysis applied to the SCL-90 scores of
subjects with opioid addiction entering a residential TC
yielded the same five-factor solution obtained for sub-
jects with opioid addiction entering an OAT. These five
dimensions have been previously discussed in the light
of the available literature on the physiopathology and
psychopathology of addiction (see Maremmani et al. [22]).
Expressed concisely, the first dimension (‘worthlessness
and being trapped’) may be explained by the close link
between mood disorders and addiction, in terms of
neurobiological background, psychological and psycho-
pathological risk factors, and the epidemiology of the
two conditions [8,26-32]. The second dimension (‘soma-
tization’) may be accounted for on the grounds of opioid
withdrawal symptomatology, which may be correlated
with the request for treatment. Withdrawal status may
also be involved in the fourth factor (‘panic-anxiety’),
due to the overlap between anxiety and withdrawal
symptomatology, and shared features in terms of neuro-
biology and physiopathology [33-35]. The third dimension
(‘sensitivity-psychoticism’) may be understood in the
light of self-treatment theory, as the consequence of the
antipsychotic action of opioids [36-43] or as a consequence
of a concomitant abuse of stimulants or cannabis [44-52].
The last dimension (‘violence-suicide’) is marked by impul-
siveness, which is a major feature of addictive behav-
iour, as can be explained by the common neurobiologicalbackground, involving the limbic system and prefrontal
cortex, and risk factors, such as antisociality and drug-
related disinhibition [53-61].
The results of the above confirmatory factor analysis
need to be discussed in the light of the heterogeneity of
the two samples considered. Actually, the two groups
(subjects with heroin addiction entering OAT and those
entering residential TC) differ in important factors related
to socio-demographic and clinical conditions, treatment
setting, and programme characteristics. As regards socio-
demographic and clinical characteristics, patients entering
OAT or TC did not differ in gender and educational level,
but they did differ in age, marital status, employment,
welfare benefits, previous treatment, and heroin history
length. Patients in the TC group were significantly older,
showed a higher percentage of singles, unemployed, and
those receiving welfare benefits. They had a statistically
significant longer history of heroin use and a greater
number of previous treatments than those in the OAT
group. As regards settings and the organization of
treatment programmes, too, the choices regarding the
two groups were clearly divergent: in the first case, there
is a highly standardized programme, such as methadone
or buprenorphine maintenance, distinguished by its scien-
tifically proven efficacy, governed by guidelines and clear
operational procedures [62-64]; in the second, a less stan-
dardized and more heterogeneous residential programme,
subject to changes and adaptations undertaken to satisfy
the needs of a special population (women, adolescents,
people affected by psychiatric comorbidity), and financial
limitations [65-68].
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from 121 TC setups in eight Italian regions [23]. These
communities differ in the variety of the services offered
(pharmacological, including opioid agonist treatment,
psychological, psychiatric, educational, social, rehabilita-
tive, and work training), for the target population (males,
mother-and-child, with a double diagnosis, with polyde-
pendence), and in the length of the treatment provided
(ranging from a few months to a few years) [23].
In spite of such a high level of heterogeneity in treat-
ment settings and programmes and of the existence of
such relevant and statistically significant differences in
socio-demographic and clinical characteristics, the SCL-
90 patterns obtained through PCA analysis are the same
for the two groups, OAT and TCs. According to these
results, the five psychological/psychiatric dimensions
(‘worthlessness-being trapped’, ‘somatic symptoms’, ‘sen-
sitivity-psychoticism’, ‘panic-anxiety’, ‘violence-suicide’) might
be considered as characteristics of the psychopathology of
subjects with opioid addiction, regardless of demographic
and clinical presentations or treatment choice.
As pointed out above, the presence of specific patterns
of psychological features or aggregates of psychiatric
symptoms in people with addiction may be explained on
the basis of the close neurobiological and neuropsycho-
logical links between addiction and other psychiatric
conditions such as those pertaining to the mood, anxiety,
or impulse control domains [12,13,31,69,70]. Clearly, some
of the symptoms involved in the five identified dominant
psychopathological groups may depend on the presence of
a known comorbid psychiatric disorder or on the presence
of a subthreshold mood, anxiety, and/or impulsive/dyscon-
trol spectrum manifestation. On the other hand, some
symptoms may reflect the severity of opioid addiction, as
well as the associated use or abuse of, or dependence on
other drugs (cocaine, alcohol, or other stimulants and
depressants), or a specific pattern of polyabuse. Currently,
the longitudinal view of the psychopathology of addictive
disorders should take into account a variety of compo-
nents, such as pre-existing psychological/psychiatric
conditions, substance effects/withdrawal symptoms, addict-
ive processes (with psychiatric manifestations related to
craving and dyscontrol), and including psychiatric conse-
quences of the interaction between pre-existing conditions
and addictive processes [13]. The interaction between all
these psychiatric determinants helps to explain why the
psychological/psychiatric presentations of people with
addiction may diverge from the classical psychiatric
nosography and be expressed, rather, through clinical
pictures that may resemble, but not be exactly identifiable
as, specifically known psychiatric disorders. Due to the deep
interaction between different psychiatric determinants,
it may be almost impossible to disentangle what pertains
to addiction from what pertains to other independentpsychopathological features. On these bases, even the
‘dual diagnosis’ construct itself has been questioned,
and the need to deepen the investigation to identify the
psychic structure of addiction is an issue that has been
raised as an immediate concern [13].
When looking at the association between the five
psychological/psychiatric dominant groups and the al-
location to TC or OAT treatment—taking into account
age, gender, heroin history length, previous treatments,
working condition, and welfare benefits as potential
confounders—‘somatic symptoms’ and ‘violence-suicide’
dominant dimensions are associated with OAT. This
could be due to the fact that the somatic dimension,
which may be closely correlated with the withdrawal
condition, as well as violence and suicide features, may
be better handled in an OAT, where the medical approach
is stronger. Regarding the other confounding factors
considered, it is plausible that patients with a short
history of heroin and/or at their first treatment, as well as
those who continue to work, may prefer a less demanding
treatment such as OAT, which is likely to have a lower
impact on their everyday life.
As regards the correlation between gender and psy-
chopathological conditions as caught by SCL-90, while it
does not seem to show any impact on patients requiring
an OAT, it has an impact on patients undertaking TC:
among these, males express a lower and females a higher
level of psychopathology than patients entering an OAT.
TCs appear to be more easily entered by females with
more intense psychiatric symptoms. Differences in psy-
chopathology between females and males with opioid
addiction have been previously documented. Previous
studies showed that females experience more serious
psychological consequences from drug dependence, as well
as a greater prevalence and severity of psychopathology
than males [71-75]. This higher psychiatric severity is also
associated with a higher level of dysfunction in the other
areas of life (medical, drug-related, employment, and fam-
ily/social) [71-73]. The preference of females for the TC
treatment might be explained by the potential advantages
offered by residential programmes in terms of the allevi-
ation of psychiatric symptoms and the management of
multiple needs. This is even more evident nowadays than
in the past, since Italian TCs now offer a large variety of
treatments, including methadone and buprenorphine treat-
ment, as well as educational, psychological, psychiatric, and
rehabilitative interventions.
Limitations
The psychological/psychiatric profiles of the subjects
involved in both the samples were based on self-
assessment through SCL-90, an instrument that is easy
to administer, requiring few instructions and only a
short time for completion. As the retrieved symptoms
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perceived by an expert interviewer. It should be noted that
since the patients were enrolled in many different care
units, an apparently ‘objective’ evaluation would have
not been possible: interviews would have been performed
by different interviewers, so involving a high risk of inter-
observer differences. We therefore preferred a patient-
related self-assessment that allowed the investigation of
symptoms in a dimensional perspective, while giving
the opportunity to record the experience of the patient
without the mediation of the examiner, rather than a
non-uniform interviewer-related objective rating. On
the other hand, it has to be acknowledged that this kind
of patient may have a low level of insight, possibly causing
his/her voluntary or involuntary hiding of some symptoms.
As a result, caution is needed in interpreting these results,
since they may be affected by the lack of any observer-
related ‘objective’ evaluation. The use of other instruments
to check the tendency of patients to lie, their understanding
of the questions that are put to them, and their motivation
to participate in the procedure would certainly substantially
improve the validity of our work.
Moreover, both samples of patients involved in our
research are lacking in any formal psychiatric diagnosis.
It must be pointed out that in Italy, psychiatric diagnosis
is often formulated late in the course of the treatment
received in addiction facilities or local addiction treatment
units. In this connection, we have to point out that our re-
search moves from the weakness of categorical psychiatric
nosography and from the tendency to attribute symptoms
expressed by addicted patients to pre-established psychi-
atric categories, such as forms of comorbidity. SCL-90
does not allow discrimination in terms of the impact of
psychiatric problems: it is likely that a formal and object-
ive psychiatric diagnosis would have made it possible to
distinguish between people who do and do not have
significant psychiatric conditions and to investigate the
relationship between SCL-90-based psychopathological
membership and psychiatric diagnosis. As a result, we
are not yet in a position to know whether or how strongly
the identified profiles are correlated with specific psychi-
atric diagnostic criteria.
A further limitation is that the SCL-90 questionnaire
was administered only at entry into treatment, so results
can only be considered representative of subjects with
heroin addiction at that particular moment. Some symp-
toms may vary at different stages of the disease, whereas
some may favour or limit certain treatment choices, so
that they may prove to be under- or overweighted in our
sample.
Moreover, the lack of information on other potential
confounders of the association of opioid addiction with
the five identified psychological/psychiatric dimensions
should be taken into account: we cannot exclude thepossibility that the identified profiles were influenced by
the presence of opioid withdrawal, by the abuse of, or
dependence on, other drugs, or by additional psychiatric
disorders. In addition, we do not know whether these
five dimensions are stable or whether they may change
during the course of addiction.
Furthermore, the OAT sample and the TC cohort
show differences in several factors (especially age and
length of addiction). In particular, although we adjusted
analyses for known confounding factors, the diagnostic
procedures followed in the two samples of patients were
clearly different: they were DSM-based for patients
entering OAT and clinically based for those entering a
TC. This may involve a misclassification bias. In this
connection, it is important to make the point that given
the implications involved in the choice of a residential
programme—particularly in terms of limitations on the
personal freedom of patients, that often result in dropouts,
and higher costs for Italian public services—clinicians are
usually required to use a careful approach to the diagnosis
of dependence, which may entail the selection of patients
who have a severe condition. In any case, the opposite
possibility—of the inclusion in the TC sample of patients
who did not reflect the full DSM diagnostic criteria—can-
not be excluded, either. Therefore, a possible under- or
overestimation of the true magnitude of the measures
of association used in our study should be taken into
consideration.
Conclusions
By looking at the entire group of answers given by patients
with opioid addiction to the SCL-90 questionnaire at their
entry into TC treatment, we obtained the same five psy-
chopathological dimensions previously seen in subjects
with opioid addiction entering an OAT. While these di-
mensions may be the expression of the links existing at the
aetiological and physiopathological levels between addiction
and other mental disorders, at this stage of the investiga-
tion, it is too early to draw any firm conclusion on the spe-
cific nature or the psychological/psychiatric determinants
of the five identified dimensions. Further research is needed
to confirm our results, to clarify the differences between
the five psychopathological subgroups and their determi-
nants, and to predict symptoms that can benefit from antic-
raving treatment or that need to be targeted separately.
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